TITLE

Efectos del tiempo de infección sobre predictores de adherencia en personas con VIH

AUTHOR(S)
Piña López, Julio Alfonso; Tapia, Mariana Dávila; Sánchez Sosa, Juan José; Robles, Óscar Cázares; Togawa, Carlos; Corrales Rascón, Andrés Ernesto
PUB. DATE
March 2009
SOURCE
International Journal of Psychology & Psychological Therapy;2009, Vol. 9 Issue 1, p67
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
A cross-sectional study was made with the main objective to prove the effects of length of infection (in months) on predictors of adherence behaviors to antiretroviral therapy in a sample of 44 persons with HIV. A multiple linear regression analysis showed that motives and stress-related to high tolerance to ambiguity predicted adherence behaviors (F[3,43]= 8,310; p= 0.000). Using length of infection (average 55 months) as a criteria variable, in the group of ≤55 months predictors were motives and low depressive symptomatology (F[2,21]= 10,435; p= 0.001), meanwhile in the group of >55 months predictors were motives and stress-related to high tolerance to frustration (F[2,21]= 11,057; p= 0.001). The results of this study support the hypothesis of a causal relationship between the lenght of infection and predictors of adherence behaviors in people with HIV, aspect that must be considere in the proccesses of desing and implementing interdisciplinary intervention programs directed to promote the consistent and efficient practice of such behaviors.
ACCESSION #
41135840

 

Related Articles

  • Forgiveness of non-adherence to HIV-1 antiretroviral therapy.  // Journal of Antimicrobial Chemotherapy (JAC);Apr2008, Vol. 61 Issue 4, p769 

    Superior adherence to HIV-1 antiretroviral therapy is a mainstay of successful HIV management. Studies performed in the early era of highly active antiretroviral therapy demonstrated the need for ≥95% adherence in order to achieve and sustain viral suppression. High rates of viral...

  • Effects of Antiretroviral Drug Recall on Perception of Therapy Benefits and on Adherence to Antiretroviral Treatment in HIV-Infected Children. Giannattasio, Antonietta; Barbarino, Alessandro; Vecchio, Andrea Lo; Bruzzese, Eugenia; Mango, Carmela; Guarino, Alfredo // Current HIV Research;Sep2009, Vol. 7 Issue 5, p468 

    In June 2007, the European Medicines Agency announced the recall by Roche of nelfinavir from European Union markets because of contamination of tablets with ethyl mesylate. Based on this event, we investigated the effect of switching therapy because of nelfinavir recall or for other reasons on...

  • CD4+ Count—Guided Interruption of Antiretroviral Treatment.  // New England Journal of Medicine;11/30/2006, Vol. 355 Issue 22, p2283 

    Background: Despite declines in morbidity and mortality with the use of combination antiretroviral therapy, its effectiveness is limited by adverse events, problems with adherence, and resistance of the human immunodeficiency virus (HIV). Methods: We randomly assigned persons infected with HIV...

  • Attacking HIV Provirus: Therapeutic Strategies to Disrupt Persistent Infection. Margolis, David M.; Archin, Nancy M. // Infectious Disorders - Drug Targets;Dec2006, Vol. 6 Issue 4, p369 

    The therapeutic armamentarium for human immunodeficiency virus type 1 (HIV-1) infection continues to expand. New targets such as entry and integration have recently been successfully exploited. However, HIV-infected patients in need of treatment are currently committed to lifelong suppressive...

  • HIV-1 Infection and Central Monoamine Neurotransmitters. Kumar, Adarsh M.; Fernandez, J. B.; Borodowsky, Irina; Gonzalez, Louis; Kumar, Mahendra // American Journal of Infectious Diseases;2007, Vol. 3 Issue 4, p177 

    Human immunodeficiency virus type 1 (HIV-1) enters the central nervous system (CNS) shortly after infection and gets localized in different brain regions, leading to various types of neuropathological problems. It has been hypothesized that HIV-1 infection mediated neuropathogenesis may also...

  • Induction of a Soluble Anti-HIV-1 factor (s) with IFN-γ, IL-10, and β-Chemokine Modulating Activity by an Influenza-Bacterial Polyantigenic Mixture. Rodríguez, José W.; Pagan, Nat O.; Ocasio, María C.; Ríos, Zilka; Cubano, Luis A.; Boukli, Nawal M.; Otero, Miguel; Hunter, Robert; Nair, Madhavan P.; Rios-Olivares, Eddy // American Journal of Infectious Diseases;2007, Vol. 3 Issue 4, p266 

    Partial immune restoration may be obtained with highly active antiretroviral therapy (HAART), but specific anti-HIV-1 immune responses do not appear to improve substantially. We have demonstrated that a soluble factor(s) induced by a mixture of inactivated influenza and bacterial vaccines called...

  • Corroborative Study Confirmed That Adding Enfuvirtide to an Optimized Antiretroviral Regimen Benefited Patients with Multidrug-Resistant HIV Infection. Lorber, Bennett // Annals of Internal Medicine;12/7/2004, Vol. 141 Issue 11, p878 

    The article presents information on papers related to infectious diseases in Europe and Australia. The paper "Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia," by A. Lazzarin, B. Clotet, D. Cooper, et al. confirmed that adding enfuvirtide to an...

  • Perspective on HIV Infection and Aging: Emerging Research on the Horizon. Casau, Nathalie C. // Clinical Infectious Diseases;9/15/2005, Vol. 41 Issue 6, p855 

    A greater prevalence of human immunodeficiency virus (HIV)-infected individuals aged >50 years is projected. This epidemiologic trend will continue to increase as a result not only of greater survival rates among HIV-infected patients who receive treatment, but also of delayed recognition of...

  • Possible Mechanism of Toxicity of Zidovudine by Induction of Apoptosis of CD4+ and CD8+ T-Cells in Vivo. Benveniste, O.; Estaquier, J.; Lelièvre, J. D.; Vildé, J. L.; Ameisen, J. C.; Leport, C. // European Journal of Clinical Microbiology & Infectious Diseases;Dec2001, Vol. 20 Issue 12, p896 

    Some HIV-infected patients have a discordant response to highly active antiretroviral therapy with a low virus load and an incomplete restoration of CD4+ T-cell counts. Zidovudine may limit CD4+ restoration by a hematotoxic mechanism. Apoptosis and T-cell counts were assessed in two patients...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics